Roivant Sciences Ltd.

General ticker "ROIV" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $8.2B (TTM average)

Roivant Sciences Ltd. follows the US Stock Market performance with the rate: 49.3%.

Estimated limits based on current volatility of 2.1%: low 10.66$, high 11.12$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-03-31 to 2026-03-31

  • 2024-03-31 to 2025-03-31 estimated range: [7.74$, 13.15$]
  • 2025-03-31 to 2026-03-31 estimated range: [6.71$, 11.80$]

Financial Metrics affecting the ROIV estimates:

  • Negative: Non-GAAP EPS, $ of -1.08 <= 0.04
  • Negative: Operating cash flow per share per price, % of -8.32 <= 1.79
  • Positive: Interest expense per share, $ of 0.04 <= 0.10
  • Negative: Industry operating cash flow per share per price (median), % of -25.87 <= 2.82
  • Positive: Operating profit margin, % of 3399.19 > 18.46
  • Negative: Industry earnings per price (median), % of -32.29 <= 0

Similar symbols

Short-term ROIV quotes

2025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-072025-05-082025-05-092025-05-1299.51010.51111.5
Price $

Long-term ROIV plot with estimates

7891011121314Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026−0.4−0.3−0.2−0.10
ROIVS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-03-31 2023-03-31 2024-03-31
Operating Revenue $55.29MM $61.28MM $124.80MM
Operating Expenses $1,406.93MM $1,236.60MM $-4,117.22MM
Operating Income $-1,351.64MM $-1,175.32MM $4,242.02MM
Non-Operating Income $427.89MM $-49.52MM $11.41MM
Interest Expense $7.04MM $27.97MM $34.78MM
R&D Expense $622.93MM $622.96MM $501.74MM
Income(Loss) $-923.75MM $-1,224.83MM $4,253.43MM
Taxes $0.37MM $5.19MM $-22.22MM
Other Income(Loss) $0.00MM $114.56MM $0.00MM
Profit(Loss)* $-845.26MM $-1,009.03MM $4,348.93MM
Stockholders Equity $1,656.94MM $1,157.77MM $5,968.58MM
Inventory $0.00MM $2.76MM $35.25MM
Assets $2,585.13MM $2,389.60MM $7,222.48MM
Operating Cash Flow $-677.73MM $-843.39MM $-765.27MM
Capital expenditure $17.44MM $12.69MM $1.38MM
Investing Cash Flow $303.30MM $-44.27MM $5,203.62MM
Financing Cash Flow $306.79MM $499.46MM $419.36MM
Earnings Per Share** $-1.26 $-1.42 $5.55

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.